Biogen BIIB

NAS: BIIB | ISIN: US09062X1037   29/11/2024
160,63 USD (+0,50%)
(+0,50%)   29/11/2024

19 november 2024 · Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity · Persbericht

14 november 2024 · Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease · Persbericht

31 oktober 2024 · Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference · Persbericht

29 oktober 2024 · Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases · Persbericht

29 oktober 2024 · Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer · Persbericht

28 oktober 2024 · Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025 · Persbericht

27 oktober 2024 · Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 · Persbericht

24 oktober 2024 · Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference · Persbericht

22 oktober 2024 · Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024 · Persbericht

9 oktober 2024 · Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients · Persbericht

8 oktober 2024 · New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA · Persbericht

24 september 2024 · UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024 · Persbericht

12 september 2024 · Biogen Board Appoints Two New Independent Directors · Persbericht

4 september 2024 · Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA · Persbericht

22 augustus 2024 · Leqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain · Persbericht

31 juli 2024 · Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen · Persbericht

30 juli 2024 · New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC) 2024 · Persbericht

30 juli 2024 · New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The Alzheimer's Association International Conference (AAIC) 2024 · Persbericht

30 juli 2024 · Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease · Persbericht

26 juli 2024 · Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union · Persbericht

Mijn selecties